Affordable Access

Access to the full text

Sustained acoustic medicine; sonophoresis for nonsteroidal anti-inflammatory drug delivery in arthritis

Authors
  • Masterson, Jack1
  • Kluge, Brett1
  • Burdette, Aaron1
  • Sr, George Lewis2
  • 1 45221, USA
  • 2 Transducer Engineering Inc., Andover, MA 01810, USA
Type
Published Article
Journal
Therapeutic Delivery
Publisher
"Future Science, LTD"
Publication Date
Jun 01, 2020
Volume
11
Issue
6
Pages
363–372
Identifiers
DOI: 10.4155/tde-2020-0009
PMID: 32657251
PMCID: PMC7373207
Source
PubMed Central
Keywords
Disciplines
  • Short Communication
License
Green

Abstract

Background: Arthritis pain is primarily managed by nonsteroidal anti-inflammatory drugs (NSAIDs), such as diclofenac. Topical diclofenac gel is limited in efficacy due to its limited penetration through the skin. This study investigates the use of a multihour, wearable, localized, sonophoresis transdermal drug delivery device for the penetration enhancement of diclofenac through the skin. Materials & methods: A commercially available, sustained acoustic medicine (sam®) ultrasound device providing 4 h, 1.3 W, 132 mW/cm2, 3 MHz ultrasound treatment was evaluated for increasing the drug delivery of diclofenac gel through a human skin model and was compared with standard of care topical control diclofenac gel. Results: Sonophoresis of the diclofenac gel for 4 h increases diclofenac delivery by 3.8× (p < 0.01), and penetration by 32% (p < 0.01). Conclusion: Sustained acoustic medicine can be used as a transdermal drug-delivery device for nonsteroidal anti-inflammatory drugs.

Report this publication

Statistics

Seen <100 times